GLPH-1 (Grapeseed Polyphenol)

GLPH-1 is a standardized grapeseed polyphenol extract characterized by a proanthocyanidin content exceeding 95%, where these oligomeric proanthocyanidins act as potent free-radical scavengers and may modulate endothelial nitric oxide synthase (eNOS) activity to support vascular tone. Its cognitive health classification stems from proposed neuroprotective effects linked to reduced oxidative stress in neuronal tissue, though direct human clinical trials specific to the GLPH-1 designation remain limited.

Origin & History

GLPH-1 (Grapeseed Polyphenol) is a branded grape seed extract derived from Vitis vinifera grape seeds, primarily from varieties like Zinfandel, Muscat, or Chardonnay. It is produced through hot water extraction at 212°F for 2 hours, followed by enzymatic treatment with pectolytic enzymes, acidification, and purification using adsorbent resins like XAD-7HP® or XAD-16®.

Historical & Cultural Context

No historical or traditional medicine context was found for GLPH-1 or grape seed polyphenols in the provided research. The ingredient appears to be a modern branded extract without documented traditional use in systems like Ayurveda or TCM.

Health Benefits

• May support cardiovascular health (evidence from similar grape seed extracts suggests pre-hypertension benefits, though specific GLPH-1 trials are lacking)
• Potential antioxidant activity from proanthocyanidin content (>95% polyphenol standardization achieved, but direct clinical evidence not available)
• Possible post-meal glycemic response support (general grape seed extract data from UC Davis, not GLPH-1 specific)
• May help maintain healthy LDL cholesterol levels (suggested by related grape seed research, no direct GLPH-1 studies)
• Cognitive health support (categorized under this group, though specific clinical evidence for GLPH-1 is absent)

How It Works

GLPH-1's oligomeric proanthocyanidins (OPCs) scavenge reactive oxygen species (ROS) by donating hydrogen atoms to neutralize superoxide and hydroxyl radicals, inhibiting lipid peroxidation cascades. These OPCs also upregulate endothelial nitric oxide synthase (eNOS) expression, increasing nitric oxide (NO) bioavailability to promote vasodilation and reduce vascular resistance. Additionally, proanthocyanidins may inhibit NADPH oxidase activity and downregulate NF-κB inflammatory signaling, which is theorized to contribute to neuroprotective effects relevant to its cognitive health category.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses directly on GLPH-1 were found in the provided research. General grape seed extract studies from UC Davis indicate potential benefits for pre-hypertension, glycemic response, and LDL cholesterol, but these lack specific study designs, sample sizes, or PMIDs and cannot be directly attributed to GLPH-1.

Clinical Summary

Direct randomized controlled trials using the specific GLPH-1 designation are not currently available in peer-reviewed literature, limiting definitive efficacy claims. However, closely related standardized grapeseed extracts (GSE) with comparable OPC profiles have been studied in small human trials; a meta-analysis of 16 randomized trials (n=810) found GSE supplementation significantly reduced systolic blood pressure by approximately 6.08 mmHg and diastolic blood pressure by 2.8 mmHg in pre-hypertensive individuals. Antioxidant outcomes in these trials, measured via plasma ORAC values and F2-isoprostane reduction, showed statistically significant improvements at doses ranging from 150–300 mg/day over 4–12 weeks. Evidence quality is moderate, and extrapolation from generic GSE data to GLPH-1 specifically must be done cautiously until proprietary trials are published.

Nutritional Profile

GLPH-1 is a highly concentrated grapeseed polyphenol extract standardized to >95% total polyphenol content, meaning it is not a whole-food ingredient and contains negligible macronutrients (protein, fat, carbohydrates) or conventional micronutrients in functional doses. Bioactive composition is dominated by oligomeric proanthocyanidins (OPCs), primarily procyanidin B1, procyanidin B2, procyanidin C1, and procyanidin B2-3-O-gallate, which are the characteristic dimeric and trimeric flavan-3-ol units of grape seed extracts. Monomeric flavan-3-ols including (+)-catechin and (-)-epicatechin are present as minor constituents, typically comprising 2–5% of the polyphenol fraction in high-OPC standardized extracts. Gallic acid and its derivatives contribute to the gallate-esterified procyanidin pool. The >95% standardization level distinguishes GLPH-1 from standard grape seed extracts (commonly 85–90% polyphenols), suggesting a more refined, higher-purity extract with reduced non-polyphenol plant matrix content (waxes, lipids, sugars). Bioavailability of grape seed OPCs is molecular-weight dependent: monomers (catechin, epicatechin) are well-absorbed in the small intestine with bioavailability estimates of 20–50%; dimers show moderate absorption; higher-order oligomers and polymers (>4 units) are poorly absorbed intact and undergo colonic microbial biotransformation into smaller phenolic acids (e.g., 3-O-methyl gallic acid, hydroxyphenylpropionic acid derivatives) that are systemically absorbed. Caloric contribution is negligible at typical supplemental doses (100–300 mg). No significant fiber, vitamin, or mineral content is expected at these concentrations.

Preparation & Dosage

No clinically studied dosage ranges for GLPH-1 are available. Extraction processes yield >95% polyphenol content with oligomeric procyanidins comprising >98% of procyanidins, but human dosing recommendations have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Resveratrol, Quercetin, Vitamin C, CoQ10, Maritime Pine Bark Extract

Safety & Interactions

Standardized grapeseed polyphenol extracts are generally well tolerated at doses up to 300 mg/day, with the most commonly reported adverse effects being mild gastrointestinal discomfort, headache, and dizziness observed in a minority of participants in clinical trials. GLPH-1's OPCs may potentiate the anticoagulant effect of warfarin and other blood thinners by inhibiting platelet aggregation and modulating thromboxane A2 synthesis, requiring caution and possible INR monitoring in patients on anticoagulant therapy. Co-administration with chemotherapy agents metabolized via CYP2C9 and CYP3A4 pathways warrants caution, as proanthocyanidins may inhibit these enzymes. Safety data in pregnant or breastfeeding individuals is insufficient, and use during pregnancy is not recommended without physician guidance.